Cannabinoids are a collection of naturally occurring chemical compounds that are situated in the marijuana plant (cannabis sativa). Cannabidiol (CBD) is the main chemical within the cannabis plant and it is said by the wide scientific community that it has anti inflammatory effects when induced into animal cells. Tetrahydrocannabinol (THC) is another one of these chemicals and it is said to have a psychotropic effect. Major cannabinoid receptors (CB1 and CB2) are located in the endocannabinoid system and gives endogenous cannabinoids power to bind and thrive in the body. This paper will review the effects of marijuana on epilepsy and how therapeutic drugs can be made with cannabinoids.
Here is the full scientific article if you wish to download it.
A therapeutic potential in the treatment of epilepsy
Phytocannabinoids isolated from the marijuana plant have broad potential in medicine that has been well applauded for many centuries. It is perceived that these lipid soluble transmissioning molecules put force on their effects in both the central and peripheral nervous system in large part through a direct relationship with metabotropic cannabinoid receptors. These same receptors are also highlighted by a variety of endogenous cannabinoids including 2-arachidonoyl glycerol and anandamide. A massive effort over the last decade has made an enormous development in the understanding of both the cellular and the synaptic physiology of endogenous lipid signaling systems. This increase in knowledge has left us better prepared to carefully review the potential for both natural and synthetic cannabinoids in the treatment of a number of neurological disorders. In the case of epilepsy, long standing interest in therapeutic angles that target endogenous cannabinoid transmissioning networks are, for the most part, not well justified by available clinical results from human epileptics. Nevertheless, basic science research have clearly suggested a key role for endogenous cannabinoid transmissioning systems in moment to moment regulation of neuronal excitability. Further it has become clear that the networks can both change and be changed by epileptiform activity in a wide range of in different models of epilepsy. All together, these observations indicate clear potential for efficient therapeutic modulation of endogenous cannabinoid transmissioning systems in the healing of human epilepsy, and in fact, further highlight key obstacles that would need to be looked at to lasso that goal.
Cannabinoids can have an anti inflammatory effect
While many of these dilemmas are indeed substantial, there are still a number of avenues through which better treatment outcomes may actually be acquired. Strategies that increase the ability to release cannabinoids when and where wanted, or to durate the activity of endogenous cannabinoids only where naturally released, may hold better vows for efficiently enhancing the brain’s own strategies for the controlling of excitability. Overall, it is seen that massive additional effort and time will be needed to develop appropriately specific therapeutic interventions for epilepsy that more precisely target selective aspects of endogenous cannabinoid systems, however convenient tools for ever more specific tweaking of brain systems continue to develop, and thus basic science should continue to strive to provide detailed mechanistic insights that will be needed to guide the use of future therapeutic apparatus.